Bulletin
Investor Alert

Market Pulse Archives

June 10, 2008, 2:11 a.m. EDT

Roche moves Ipsen diabetes drug to Phase III trials

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Ipsen (IPN)
  • X
    Roche Holding AG ADR (RHHBY)

or Cancel Already have a watchlist? Log In

By Robert Daniel

TEL AVIV (MarketWatch) -- Ipsen, /zigman2/quotes/200122335/delayed FR:IPN -1.47% the Paris drugmaker, said that Roche /zigman2/quotes/208994986/composite RHHBY +0.64% is moving taspoglutide, a once-weekly treatment for obese patients with type 2 diabetes, into Phase III clinical trials, the companies said in a statement on Tuesday. Patients saw "significant improvements in glucose control and weight loss after only eight weeks of treatment" with Ipsen's taspoglutide, they said. The Phase III trials should begin in the second half. In 2006, Roche, the Basel health-care giant, exercised an option to license taspoglutide from Ipsen. Roche acquired rights to develop and market the drug worldwide, except in Japan, where it shares the rights with Teijin, /zigman2/quotes/204413441/composite TINLY +2.05% /zigman2/quotes/204006550/delayed JP:3401 -0.30% and in France, where Ipsen may choose to co-market the drug.

/zigman2/quotes/200122335/delayed
FR : France: Euronext Paris
107.20
-1.60 -1.47%
Volume: 356,103
Nov. 30, 2022 5:35p
P/E Ratio
12.05
Dividend Yield
1.12%
Market Cap
€9.00 billion
Rev. per Employee
€513,980
loading...
/zigman2/quotes/208994986/composite
US : U.S.: OTC
$ 40.92
+0.26 +0.64%
Volume: 1.98M
Nov. 30, 2022 4:00p
P/E Ratio
17.31
Dividend Yield
1.90%
Market Cap
$267.31 billion
Rev. per Employee
$684,378
loading...
/zigman2/quotes/204413441/composite
US : U.S.: OTC
$ 9.44
+0.19 +2.05%
Volume: 28.00
Nov. 28, 2022 3:30p
P/E Ratio
25.44
Dividend Yield
3.65%
Market Cap
$1.83 billion
Rev. per Employee
$362,819
loading...
/zigman2/quotes/204006550/delayed
JP : Japan: Tokyo
¥ 1,324.00
-4.00 -0.30%
Volume: 329,600
Dec. 1, 2022 11:13a
P/E Ratio
28.26
Dividend Yield
3.02%
Market Cap
¥255.29 billion
Rev. per Employee
¥45.07M
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.